PMV Pharmaceuticals 과거 순이익 실적

과거 기준 점검 0/6

PMV Pharmaceuticals의 수입은 연평균 -7%의 비율로 감소해 온 반면, Biotechs 산업의 수입은 연간 33.8% 증가했습니다.

핵심 정보

-6.96%

순이익 성장률

0.52%

주당순이익(EPS) 성장률

Biotechs 산업 성장률	17.04%
매출 성장률	n/a
자기자본이익률	-89.06%
순이익률	n/a
최근 순이익 업데이트	31 Mar 2026

최근 과거 실적 업데이트

업데이트 없음

Recent updates

분석 기사 • May 19

Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

분석 기사 • Apr 20

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

분석 기사 • Dec 22

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

분석 기사 • Sep 08

We Think PMV Pharmaceuticals (NASDAQ:PMVP) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

분석 기사 • May 10

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

분석 기사 • Jan 11

PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

분석 기사 • Sep 22

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Seeking Alpha • Aug 09

PMV Pharmaceuticals GAAP EPS of -$0.38 beats by $0.04

PMV Pharmaceuticals press release (NASDAQ:PMVP): Q2 GAAP EPS of -$0.38 beats by $0.04. cash equivalents, and marketable securities of $277.4m

Seeking Alpha • Jul 18

PMV Pharma joins Merck to study lead candidate with Keytruda

Cancer-focused biotech PMV Pharmaceuticals (NASDAQ:PMVP) announced an agreement with Merck (MRK) on Monday to study its lead product candidate PC14586 in combination with Merck’s (MRK) anti-PD-1 therapy Keytruda in advanced solid tumors. Accordingly, PMV (PMVP) will add a combination arm to study the experimental drug in the company’s ongoing Phase 1/2 PYNNACLE trial for patients with advanced solid tumors. The combination arm, designed to assess PC14586/ Keytruda combo in patients with advanced solid tumors harboring a p53 Y220C mutation, is expected to recruit about 36 subjects. Per the terms, PMV Pharma (PMVP) will sponsor the study, and Merck (MRK) will supply Keytruda. PC14586 is an investigational small molecule designed to selectively target the p53 Y220C mutation of cancers. Read: PMV (PMVP) traded lower last month after the company announced early data from the PYNNACLE trial for PC14586.

분석 기사 • Jun 09

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

분석 기사 • Feb 23

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

분석 기사 • Nov 05

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

분석 기사 • Jul 23

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

분석 기사 • Apr 09

PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Strong Position To Grow Its Business

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

분석 기사 • Dec 25

Do Institutions Own PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares?

Every investor in PMV Pharmaceuticals, Inc. ( NASDAQ:PMVP ) should be aware of the most powerful shareholder groups...

매출 및 비용 세부 내역

PMV Pharmaceuticals가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.

순이익 및 매출 추이

NasdaqGS:PMVP 매출, 비용 및 순이익 (USD Millions)
날짜	순이익	일반관리비	연구개발비
31 Mar 26	-78	16	68
31 Dec 25	-78	16	70
30 Sep 25	-83	24	67
30 Jun 25	-81	25	66
31 Mar 25	-61	26	63
31 Dec 24	-59	21	58
30 Sep 24	-51	21	58
30 Jun 24	-49	22	55
31 Mar 24	-65	23	53
31 Dec 23	-69	24	56
30 Sep 23	-73	25	58
30 Jun 23	-74	25	58
31 Mar 23	-74	25	55
31 Dec 22	-73	25	52
30 Sep 22	-72	25	49
30 Jun 22	-69	25	45
31 Mar 22	-65	24	41
31 Dec 21	-58	22	36
30 Sep 21	-50	20	31
30 Jun 21	-44	17	27
31 Mar 21	-39	13	25
31 Dec 20	-34	11	24
30 Sep 20	-31	8	23
30 Jun 20	-28	7	22
31 Mar 20	-27	6	22
31 Dec 19	-25	6	21

양질의 수익: PMVP 은(는) 현재 수익성이 없습니다.

이익 마진 증가: PMVP는 현재 수익성이 없습니다.

잉여현금흐름 대비 순이익 분석

과거 순이익 성장 분석

수익추이: PMVP은 수익성이 없으며 지난 5년 동안 손실이 연평균 7% 증가했습니다.

성장 가속화: 현재 수익성이 없어 지난 1년간 PMVP의 수익 성장률을 5년 평균과 비교할 수 없습니다.

수익 대 산업: PMVP은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(43%)와 비교하기 어렵습니다.

자기자본이익률

높은 ROE: PMVP는 현재 수익성이 없으므로 자본 수익률이 음수(-89.06%)입니다.

총자산이익률

투하자본수익률

우수한 과거 실적 기업을 찾아보세요

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/05/26 19:57
종가	2026/05/26 00:00
수익	2026/03/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

PMV Pharmaceuticals, Inc.는 9명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Gregory Harrison	BofA Global Research
Gum-Ming Lowe	Craig-Hallum Capital Group LLC
Joshua Schimmer	Evercore ISI

PMV Pharmaceuticals 과거 순이익 실적

과거 기준 점검 0/6

핵심 정보

최근 과거 실적 업데이트

Recent updates

PMV Pharmaceuticals (NASDAQ:PMVP) Will Have To Spend Its Cash Wisely

Price target decreased by 8.8% to US$4.33

PMV Pharmaceuticals, Inc. Announces Board Changes, Effective June 4, 2026

PMV Pharmaceuticals, Inc., Annual General Meeting, Jun 04, 2026

New minor risk - Share price stability

PMV Pharmaceuticals, Inc. Announces First-In-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors

New major risk - Revenue and earnings growth

Will PMV Pharmaceuticals (NASDAQ:PMVP) Spend Its Cash Wisely?

Price target decreased by 9.5% to US$7.60

Co-Founder exercised options to buy US$310k worth of stock.

PMV Pharmaceuticals, Inc. Announces Updated Rezatapopt Monotherapy Interim Data from Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors with TP53 Y220C Mutation

PMV Pharmaceuticals, Inc. Announces Promising Rezatapopt Monotherapy Interim Data from PYNNACLE Phase 2 Trial Across Multiple Solid Tumors with A TP53 Y220C Mutation

New minor risk - Share price stability

Co-Founder recently sold US$62k worth of stock

Will PMV Pharmaceuticals (NASDAQ:PMVP) Spend Its Cash Wisely?

PMV Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2025

New major risk - Revenue and earnings growth

PMV Pharmaceuticals, Inc. Provides A Progress Update on PYNNACLE Clinical Trial

Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Deliver On Growth Plans?

PMV Pharmaceuticals, Inc.(NasdaqGS:PMVP) dropped from Russell 3000 Index

Insufficient new directors

PMV Pharmaceuticals, Inc., Annual General Meeting, Jun 06, 2024

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Price target decreased by 54% to US$5.67

PMV Pharmaceuticals, Inc. Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220c-Positive Solid Tumors

PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer

PMV Pharmaceuticals, Inc. Announces Workforce Reduction of Approximately 30%

New minor risk - Market cap size

PMV Pharmaceuticals, Inc. Announces Chief Financial Officer Changes

PMV Pharmaceuticals, Inc. Announces Executive Changes

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Price target decreased by 39% to US$13.20

New minor risk - Market cap size

PMV Pharmaceuticals, Inc. Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types with TP53 Y220C Mutation

New major risk - Share price stability

PMV Pharmaceuticals, Inc. to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

We Think PMV Pharmaceuticals (NASDAQ:PMVP) Can Afford To Drive Business Growth

New minor risk - Share price stability

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans

Price target decreased to US$38.50

PMV Pharmaceuticals, Inc. Announces Board Changes

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

PMV Pharmaceuticals GAAP EPS of -$0.38 beats by $0.04

PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

PMV Pharma joins Merck to study lead candidate with Keytruda

PMV Pharmaceuticals, Inc.(NasdaqGS:PMVP) dropped from Russell 2000 Growth Index

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

PMV Pharmaceuticals, Inc. Announces Preliminary Results from the Ongoing Phase 1/2 PYNNACLE Study of PC14586 in Patients

Price target decreased to US$43.33

PMV Pharmaceuticals, Inc. to Present PC14586 Phase 1 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Price target decreased to US$49.00

PMV Pharmaceuticals, Inc., Annual General Meeting, Jun 02, 2022

Price target decreased to US$53.17

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Chief Medical Officer exercised options and sold US$103k worth of stock

Co-Founder notifies of intention to sell stock

Insider exercised options and sold US$88k worth of stock

COO & CFO exercised options and sold US$138k worth of stock

Co-Founder notifies of intention to sell stock

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

COO & CFO exercised options and sold US$137k worth of stock

PMV Pharmaceuticals, Inc.(NasdaqGS:PMVP) dropped from Russell 2500 Value Index

Co-Founder notifies of intention to sell stock

Key Executive exercised options and sold US$832k worth of stock

Co-Founder notifies of intention to sell stock

COO & CFO exercised options and sold US$137k worth of stock

Chief Medical Officer exercised options and sold US$120k worth of stock

PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Strong Position To Grow Its Business

PMV Pharmaceuticals, Inc. Appoints Guillermina Lozano to Scientific Advisory Board

New 90-day high: US$61.51

Do Institutions Own PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares?

PMV Pharmaceuticals, Inc. Doses First Patient in Phase 1/2 Study of PC14586, a First-In-Class Precision Oncology Therapy That Targets Mutant P53

Pmv Pharmaceuticals, Inc. Grants Fda Fast Track Designation of Pc14586 for the Treatment of Advanced Cancer Patients That Have Tumors with A P53 Y220c Mutation